样式: 排序: IF: - GO 导出 标记为已读
-
Cost–Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-04-15 Penglei Chen, Yixiang Wang, Xin Liu, Jiaqi Yu, Xuwei Zheng
-
Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-04-08 Hon Jen Wong, Norman H. Lin, Yao Neng Teo, Nicholas L. Syn, Yao Hao Teo, Ching-Hui Sia
-
Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020 Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-04-07
Abstract Background Landmark clinical trials have expended the indications for the direct oral anticoagulants (DOACs), but contemporary data on usage and expenditure patterns are lacking. Objective This study aimed to assess annual trends in oral anticoagulant (OAC) utilization and expenditure across the United States (US) from 2014 to 2020. Methods We utilized the Medical Expenditure Panel Survey
-
Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-04-05 Ishaque Hameed, Syeda Ayesha Shah, Ashnah Aijaz, Hasan Mushahid, Syed Husain Farhan, Muhammad Dada, Adam Bilal Khan, Reeha Amjad, Fawad Alvi, Mustafa Murtaza, Zaid Zuberi, Mohammad Hamza
-
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-04-04 Hiroaki Hiraiwa, Takahiro Okumura, Toyoaki Murohara
-
Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-04-04
Abstract Background Data are limited regarding guideline-directed medical therapy (GDMT) treatment patterns in patients with worsening heart failure (HF). Methods We used administrative claims databases in Germany and the USA to conduct a retrospective cohort study of patients with worsening HF. Two cohorts of patients with prevalent HF and a HF hospitalization (HFH) from 2016 to 2019, alive at discharge
-
Digoxin is Not Related to Mortality in Patients with Heart Failure: Results from the SELFIE-TR Registry Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-04-04 Rengin Çetin Güvenç, Tolga Sinan Güvenç, Mert Efe Çağlar, Abdullah Ayar Al Arfaj, Ailin Behrad, Mehmet Birhan Yılmaz
Aims Digoxin has been used in the treatment for heart failure for centuries, but the role of this drug in the modern era is controversial. A particular concern is the recent observational findings suggesting an increase in all-cause mortality with digoxin, although such observations suffer from biased results since these studies usually do not provide adequate compensation for the severity of disease
-
Advancing Guideline-Directed Medical Therapy in Heart Failure: Overcoming Challenges and Maximizing Benefits Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-04-03 Zixi Zhang, Cancan Wang, Tao Tu, Qiuzhen Lin, Jiabao Zhou, Yunying Huang, Keke Wu, Zeying Zhang, Wanyun Zuo, Na Liu, Yichao Xiao, Qiming Liu
The delayed titration of guideline-directed drug therapy (GDMT) is a complex event influenced by multiple factors that often result in poor prognosis for patients with heart failure (HF). Individualized adjustments in GDMT titration may be necessary based on patient characteristics, and every clinician is responsible for promptly initiating GDMT and titrating it appropriately within the patient’s tolerance
-
Efficacy of Intravenous Iron in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: A Systematic Review and Meta-Analysis of Randomized Control Trials Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-03-22 Andrew Sephien, Denisse Camille Dayto, Tea Reljic, Xavier Prida, Joanna M. Joly, Matthew Tavares, Jason N. Katz, Ambuj Kumar
-
The Rationale for Using Fixed-Dose Combination Therapy in the Management of Hypertension in Colombia: A Narrative Review Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-03-15
Abstract Hypertension is a major risk factor for cardiovascular disease and the leading cause of death in Colombia. While the rate of hypertension awareness in Colombia is generally high, rates of treatment initiation, adherence, and blood pressure (BP) control are suboptimal. Major international hypertension guidelines recommend starting treatment with a combination of antihypertensive agents, and
-
New Perspectives on the Role and Therapeutic Potential of Melatonin in Cardiovascular Diseases Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-03-04 Pengchen Gu, Yuxin Wu, Weiwei Lu
-
Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-02-28
Abstract Background Recent evidence suggests that acetazolamide may be beneficial as an adjunctive diuretic therapy in patients with acute decompensated heart failure (HF). We aim to pool all the studies conducted until now and provide updated evidence regarding the role of acetazolamide as adjunctive diuretic in patients with acute decompensated HF. Methods PubMed/Medline, Cochrane Library, and Scopus
-
Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-02-27
Abstract Background The DAPA-HF and DELIVER trials demonstrated the clinical benefits of dapagliflozin in heart failure (HF) patients across the entire ejection fraction (EF) spectrum. However, further investigation is needed for the real-world application of dapagliflozin in HF patients. This study examines the proportion of real-world HF patients eligible for dapagliflozin and evaluates the cost-effectiveness
-
Comparative Effectiveness and Safety of Direct Oral Anticoagulants Compared with Warfarin in Patients with Low Bodyweight who have Atrial Fibrillation: A Systematic Review and Meta-analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-02-22 Mohamed Nabil Elshafei, Ahmed El-Bardissy, Muhammad Salem, Mohamed S. Abdelmoneim, Ahmed Khalil, Sherine Elhadad, Mohammed Danjuma
-
Management of Hypertension in the Asia-Pacific Region: A Structured Review Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-02-08 Abdul R. A. Rahman, Jose Donato A. Magno, Jun Cai, Myint Han, Hae-Young Lee, Tiny Nair, Om Narayan, Jiampo Panyapat, Huynh Van Minh, Rohit Khurana
-
Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-02-01 Jie-Jiu Lu, Tao-Tao Liu
-
Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-02-01 Ioannis Bellos, Smaragdi Marinaki, Pagona Lagiou, Vassiliki Benetou
-
SAMe-TT2R2 Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-01-22 Natnicha Poonchuay, Surasak Saokaew, Supatcha Incomenoy
-
Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2024-01-19 Ahmed Atia, Heba Aboeldahab, Ahmed Wageeh, Mohamed Elneny, Mohamed Elmallahy, Bashaer Elawfi, Menna M. Aboelkhier, Amr Elrosasy, Maya Magdy Abdelwahab, Somaya Sayed, Ahmed Abdelaziz
-
SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-12-29 Stephen J. Greene, Gregg C. Fonarow, Javed Butler
-
Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-12-29 Seyed Ali Mousavi-Aghdas, Ebrahim Farashi, Nasim Naderi
-
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-12-28 Andre Lamy, John Eikelboom, Wesley Tong, Fei Yuan, Shrikant I. Bangdiwala, Jackie Bosch, Stuart Connolly, Eva Lonn, Gilles R. Dagenais, Kelley R. H. Branch, Wei-Jhih Wang, Deepak L. Bhatt, Jeffrey Probstfield, Georg Ertl, Stefan Störk, P. Gabriel Steg, Victor Aboyans, Isabelle Durand-Zaleski, Lars Ryden, Salim Yusuf
-
Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-12-24
Abstract Introduction Infection may induce thrombotic and hemorrhagic events; however, it is currently unclear whether the inflammatory response affects the coagulation function and the clinical efficacy and safety of rivaroxaban in older patients with non-valvular atrial fibrillation (NVAF). Objective This project aimed to assess the effectiveness and safety of the non-vitamin K antagonist oral anticoagulant
-
Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-11-23 Mostafa Reda Mostafa, Mohamed Magdi Eid, Ahmed K. Awad, Andrew Takla, Abdul Rhman Hassan, Basant E. Katamesh, Majd M. AlBarakat, Abdul Rhman Ziada, Sarah Mohamed, Karim M. Al-Azizi, Andrew M. Goldsweig
-
The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-11-17 Ryaan EL-Andari, Nicholas M. Fialka, Jimmy Kang, Sabin J. Bozso, Jayan Nagendran, Jeevan Nagendran
-
A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-11-09 Omnia Azmy Nabeh, Alaa I. Saud, Basma Amin, Amira Samy Khedr, Alaa Amr, Aml Medhat Faoosa, Eshraka Esmat, Yasmeen Magdy Mahmoud, Aya Hatem, Mariam Mohamed, Alaa Osama, Youssef Mohamed Amin Soliman, Reem Ibrahim Elkorashy, Soha Aly Elmorsy
-
Intravenous Diltiazem Versus Metoprolol in Acute Rate Control of Atrial Fibrillation/Flutter and Rapid Ventricular Response: A Meta-Analysis of Randomized and Observational Studies Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-10-19 Alexander Bolton, Bishow Paudel, Mehul Adhaduk, Mohammed Alsuhaibani, Riley Samuelson, Marin L. Schweizer, Denice Hodgson-Zingman
-
Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-10-17 Takeshi Morimoto, Haruhiko Hoshino, Yukako Matsuo, Tatsuki Ibuki, Kayoko Miyata, Yukihiro Koretsune
-
Cardioprotective Strategies After Ischemia–Reperfusion Injury Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-10-10 Honghong Zhang, Huilin Hu, Changlin Zhai, Lele Jing, Hongen Tian
-
Colchicine for the Prevention of Recurrent Arrhythmia After Catheter Ablation of Atrial Fibrillation: Results of a Single-Center, Retrospective Study Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-10-06 Kristen Bova Campbell, Stephanie Dougherty Eickman, Tracy Truong, Eric Black-Maier, Adam S. Barnett, Allen Wang, Cynthia L. Green, James P. Daubert, Robert K. Lewis, Brett D. Atwater, Sana M. Al-Khatib, Tristram D. Bahnson, Kevin L. Thomas, Kevin P. Jackson, Larry R. Jackson, Sean Pokorney, Camille Frazier-Mills, Jonathan P. Piccini
-
The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-09-05 Luis Antonio Alcocer, Alfonso Bryce, David De Padua Brasil, Joffre Lara, Javier Moreno Cortes, Daniel Quesada, Pablo Rodriguez
-
The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu? Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-09-08 Theocharis Koufakis, Ioanna Zografou, Michael Doumas, Kalliopi Kotsa
-
Novel Therapeutic Avenues for Hypertrophic Cardiomyopathy Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-09-05 Dipti Patil, Lokesh Kumar Bhatt
-
Bempedoic Acid can Reduce Cardiovascular Events in Combination with Statins or As Monotherapy: A Systematic Review and Meta-analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-09-06 Ju Zhang, Xiangfeng Guan, Baixue Zhang, Jia Wang, Xiaodong Jin, Yunhe Zhao, Bo Li
-
Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: Update of Systematic Review and Meta-Analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-28 Tong Hu, Yi-Han Li, Wen-Qiang Han, Kellina Maduray, Tong-Shuai Chen, Li Hao, Jing-Quan Zhong
-
Double Trouble: The Challenge of Neuroprotection in Patients with Liver Cirrhosis and Atrial Fibrillation. Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-28 Taha Ahmed,Adrian W Messerli
-
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-24 Ilaria Cavallari, Simone Pasquale Crispino, Andrea Segreti, Gian Paolo Ussia, Francesco Grigioni
-
SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-24 Yali Zhang, Yufeng He, Siqi Liu, Li Deng, Yumei Zuo, Keming Huang, Bin Liao, Guang Li, Jian Feng
-
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-23 Jose Seijas-Amigo, Mª José Mauriz-Montero, Pedro Suarez-Artime, Mónica Gayoso-Rey, Ana Estany-Gestal, Antonia Casas-Martínez, Lara González-Freire, Ana Rodriguez-Vazquez, Natalia Pérez-Rodriguez, Laura Villaverde-Piñeiro, Concepción Castro-Rubinos, Esther Espino-Faisán, Moisés Rodríguez-Mañero, Alberto Cordero, José R. González-Juanatey
-
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-23 Wei-Chieh Lee, Chih-Yuan Fang, Yi-Hsuan Tsai, Yun-Yu Hsieh, Tien-Yu Chen, Yen-Nan Fang, Huang-Chung Chen, Po-Jui Wu, Hsiu-Yu Fang
-
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-02 Yinxue Guo, Pingyu Ge, Ziju Li, Jingxia Xiao, Lirui Xie
-
An Opportune Time to Consider Glucose–Insulin–Potassium Therapy for Takotsubo Syndrome Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-01 John E. Madias
-
Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-07-31 Yilin Xiong, Yan Wang, Tao Yang, Yunmei Luo, Shangfu Xu, Lisheng Li
-
Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-07-31 Muhammad Shayan Khan, Ghulam Mujtaba Ghumman, Abdul Baqi, Jay Shah, Muhammad Aziz, Tanveer Mir, Ayesha Tahir, Srinivas Katragadda, Hemindermeet Singh, Mohammed Taleb, Syed Sohail Ali
-
Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-08-01 Sneha Annie Sebastian, Inderbir Padda, Eric J. Lehr, Gurpreet Johal
-
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-07-24 Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch, Thomas Michaeli
-
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-07-03 Min Chul Kim, Youngkeun Ahn, Moo Hyun Kim, Seok-Yeon Kim, Taek Jong Hong, Moo-Yong Rhee, Sang-Hyun Kim, Soon-Jun Hong, Hyungseop Kim, Weon Kim, In Ho Chae, Duk-hyun Kang, Byeong-Keuk Kim, Hyo-Soo Kim
-
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-06-23 Harsha Teja Perla, Viji Samuel Thomson, Thomas V. Attumalil, Tulasi Geevar, Anoop George Alex, Rutvi G. Dave, Sukesh C. Nair, S. Mahasampath Gowri, Prem K. Mony, Paul George, George Joseph
-
The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-06-23 Mohamed Abuelazm, Soumya Kambalapalli, Othman Saleh, Mohamed A. Elzeftawy, Khaled Albakri, Ibrahim Gowaily, Basel Abdelazeem
-
A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-06-10 Inmaculada Hernandez, Victoria Divino, Lin Xie, David W. Hood, Mitch DeKoven, Wanjiku Kariuki, Griffith Bell, Cristina Russ, Dong Cheng, Matthew Cato, Nipun Atreja, Dionne M. Hines
-
Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-06-06 Jessica Huston, Ariana Genovese, Andrea Ashchi, Amanda DeLuca, Jordyn Wiener, Elias Deeb, Alexander Deeb, Rebecca F. Goldfaden
Patients with arrythmias are at an increased risk of heart-related comorbidities and complications. Specifically, patients with paroxysmal supraventricular tachycardia (PSVT), a type of arrythmia, are at increased risk of lightheadedness or shortness of breath, due to the increased rate of the heartbeat. Most patients are prescribed oral medications to control their heart rates and maintain a normal
-
Bayesian Network Meta-analysis of Randomized Controlled Trials on the Efficacy of Antiarrhythmics in the Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-05-26 Daniele Orso, Sara Santangelo, Nicola Guglielmo, Tiziana Bove, Francesco Cilenti, Lorenzo Cristiani, Roberto Copetti
-
Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-05-18 Junyu Xu, Peihong Sun, Xia Zhao, Lei Meng, Xiaorui Wang, Xiaoyan Qin, Ying Zhou, Mingdong Zhou, Yimin Cui
-
Cost-Effectiveness and Budget Impact of a Novel Antithrombotic Drug Removal System to Reduce Bleeding Risk in Patients on Preoperative Ticagrelor Undergoing Cardiac Surgery Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-05-19 Benjamin G. Cohen, Francine Chingcuanco, Jingwei Zhang, Natalie M. Reid, Victoria Lee, Jonathan Hong, Efthymios N. Deliargyris, William V. Padula
-
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-05-15 Jessica Huston, Hannah Schaffner, Alyssa Cox, Alexander Sperry, Shelby Mcgee, Payeng Lor, Logan Langley, Blake Skrable, Majdi Ashchi, Mohannad Bisharat, Ashwini Gore, Thomas Jones, David Sutton, Mae Sheikh-Ali, Jason Berner, Rebecca Goldfaden
Icosapent ethyl (IPE) was the first fish oil product the US Food and Drug Administration (FDA) approved to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in adults. IPE is an esterified version of eicosapentaenoic acid (EPA) and acts as a prodrug in the body to exert its effects. IPE affects the body primarily through triglyceride (TG) reduction and was initially indicated for hypertriglyceridemia
-
The Single-Syringe Versus the Double-Syringe Techniques of Adenosine Administration for Supraventricular Tachycardia: A Systematic Review and Meta-Analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-05-10 Isabele A. Miyawaki, Cintia Gomes, Vittoria Caporal S. Moreira, Isabela R. Marques, Isabela A. F. de Souza, Caroliny H. A. Silva, José Eduardo Riceto Loyola Júnior, Kangwook Huh, Marc McDowell, Eduardo M. H. Padrao, Matthew B. Tichauer, Charles Michael Gibson
-
Adenosine Administration in Supraventricular Tachycardia: Single- or Double-Syringe Technique? Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-05-10 Marco Zuin,Gianluca Rigatelli
-
Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-05-05 Anne-Céline Martin, Robert Benamouzig, Isabelle Gouin-Thibault, Jeannot Schmidt
-
Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-04-28 Albert A. Volkl, Kenneth Todd Moore, Lloyd Haskell, Elliot S. Barnathan
Patients with chronic kidney disease are at an increased risk of venous thromboembolism (VTE). The factor Xa inhibitor rivaroxaban has been shown to provide similar efficacy and a lower risk of bleeding compared with vitamin K antagonists for the treatment and prevention of VTE. Rivaroxaban has been studied in patients with varying degrees of renal impairment, and this review summarizes current knowledge
-
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis Am. J. Cardiovasc. Drugs (IF 3.0) Pub Date : 2023-04-17 Hilmi Alnsasra, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Jean Marc Weinstein, Joseph Azuri, Ariel Hammerman, Ronen Arbel